The three-day negotiation of the 2021 National Medical Insurance Drug List came to an end in Beijing.
According to the latest news from the National Medical Insurance Administration, the 1.2 million yuan Akilunza injection passed the preliminary formal review, but it did not enter the negotiation link of the medical insurance catalog.
According to reports, the more expensive drugs passed the preliminary formal review, which only means that the drug meets the application requirements after the preliminary review and is qualified to enter the next adjustment link.
Whether a drug can finally enter the national medical insurance drug list will be subject to rigorous review including economics, and exclusive drugs will also undergo price negotiations.
(Reporter Peng Yunjia)